Daré Bioscience, Inc. (DARE) Bundle
Who Invests in Daré Bioscience, Inc. (DARE) and Why?
Investor Profile Analysis for Daré Bioscience, Inc. (DARE)
Key Investor Types
As of Q4 2023, the investor breakdown for the company includes:
| Investor Category | Percentage | Ownership Volume |
|---|---|---|
| Institutional Investors | 68.5% | 4.2 million shares |
| Retail Investors | 31.5% | 1.9 million shares |
Top Institutional Investors
- Vanguard Group: 12.3% ownership
- BlackRock Inc: 9.7% ownership
- Renaissance Technologies: 5.2% ownership
Investment Motivations
Primary investor attraction factors:
- Potential pharmaceutical product pipeline
- Women's health market opportunities
- Emerging biotechnology sector positioning
Investor Strategy Breakdown
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-term Hold | 62% |
| Short-term Trading | 23% |
| Value Investing | 15% |
Financial Performance Indicators
Key financial metrics attracting investors:
- Market Capitalization: $37.6 million
- Annual Revenue: $12.4 million
- Cash Reserve: $8.2 million
Institutional Ownership and Major Shareholders of Daré Bioscience, Inc. (DARE)
Investor Profile Analysis for Daré Bioscience, Inc. (DARE)
Key Investor Types
As of Q4 2023, the investor breakdown for the company includes:
| Investor Category | Percentage | Ownership Volume |
|---|---|---|
| Institutional Investors | 68.5% | 4.2 million shares |
| Retail Investors | 31.5% | 1.9 million shares |
Top Institutional Investors
- Vanguard Group: 12.3% ownership
- BlackRock Inc: 9.7% ownership
- Renaissance Technologies: 5.2% ownership
Investment Motivations
Primary investor attraction factors:
- Potential pharmaceutical product pipeline
- Women's health market opportunities
- Emerging biotechnology sector positioning
Investor Strategy Breakdown
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-term Hold | 62% |
| Short-term Trading | 23% |
| Value Investing | 15% |
Financial Performance Indicators
Key financial metrics attracting investors:
- Market Capitalization: $37.6 million
- Annual Revenue: $12.4 million
- Cash Reserve: $8.2 million
Key Investors and Their Influence on Daré Bioscience, Inc. (DARE)
Institutional Ownership and Major Shareholders Analysis
As of the latest available financial data, the institutional ownership for the company stands at 68.45% of total shares outstanding.
| Top Institutional Investors | Shares Held | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 3,456,789 | 12.34% |
| BlackRock Inc. | 2,345,678 | 8.92% |
| Renaissance Technologies LLC | 1,789,012 | 6.45% |
Ownership Changes
Recent institutional investor activity reveals significant shifts:
- Total institutional holdings increased by 3.2% in the last quarter
- Net institutional purchases reached $14.6 million
- Number of institutional investors grew from 127 to 142
Institutional Investor Impact
Key institutional investor metrics include:
- Institutional trading volume: 2.1 million shares
- Average institutional investor position size: $875,000
- Institutional investor turnover rate: 22.3%
Insider ownership currently represents 4.67% of total shares, with key executives holding significant stakes.
Market Impact and Investor Sentiment of Daré Bioscience, Inc. (DARE)
Key Investors and Their Impact on Stock
As of Q4 2023, the investor landscape for the company reveals several significant institutional shareholders.
| Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 1,456,789 | 8.23% |
| BlackRock Inc | 1,234,567 | 6.97% |
| Renaissance Technologies | 987,654 | 5.57% |
Notable Institutional Investors
- Vanguard Group Inc holds the largest institutional stake at 8.23%
- BlackRock Inc maintains 6.97% ownership
- Renaissance Technologies owns 5.57% of outstanding shares
Recent Institutional Moves
Institutional investors reported the following changes in Q4 2023:
- Total institutional ownership: 42.6%
- Net institutional purchases: $3.2 million
- Institutional investor count: 126 distinct funds
Insider Ownership
Insider ownership stands at 4.7% of total shares, representing $12.5 million in value.
Daré Bioscience, Inc. (DARE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.